Showing results (141-150 of 17,196) with videos related to
Sort By:
Pageof 1,720
Pharmacological Reviews|December 21, 2000
Yeast mutants as a model system for identification of determinants of chemosensitivityP Perego, G S Jimenez, L Gatti, et al.British Journal of Cancer|February 1, 1994
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitroA P Jekunen, R D Christen, D R Shalinsky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
The pharmacology of intraperitoneally administered bleomycinS B Howell, M Schiefer, P A Andrews, et al.Molecular Pharmacology|July 11, 1998
Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutantsP Perego, F Zunino, N Carenini, et al.Cancer Treatment Reports|April 1, 1985
Modulation of the activity of PALA by dipyridamoleT C Chan, B Young, M E King, et al.Cancer Chemotherapy and Pharmacology|January 1, 1995
Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell linesB Nakata, K D Albright, R M Barton, et al.The American Journal of Medicine|January 1, 1985
Infectious peritonitis in patients receiving intraperitoneal chemotherapyR A Kaplan, M Markman, W E Lucas, et al.Cancer Research|June 15, 1989
Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamoleS B Howell, D Hom, R Sanga, et al.Cancer Research|October 19, 2001
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repairA Kondo, R Safaei, M Mishima, et al.Cancer Research|January 1, 1988
Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patientsT C Chan, G L Coppoc, S Zimm, et al.Pageof 1,720